The following article is sourced from the Biopharmaceutical Alliance. , Author Biomedical Industry Alliance
On June 28, 2024, the Global Biomedical Conference 2024, hosted by the Zhongguancun Lianxin Biomedical Industry Alliance, was grandly held at the Exhibition Center Conference Center of the Zhongguancun National Independent Innovation Demonstration Zone.The conference brought together relevant departments and bureaus of Beijing, as well as participants from all over China.More than 450 companies, over 60 medical institutions, more than 20 investment firms, and over 10 universities, with a total of 600 attendees., and jointly discuss important topics such as industry development trends, policy guidance, technological innovation, and international cooperation.At the opening ceremony,Linhang, Deputy District Chief of Haidian District, Beijing, and Fan Yubo, Dean of the School of Biological Science and Medical Engineering at Beihang University, delivered speeches. Liu Qinghua, Deputy Director of the Beijing Center for Disease Control and Prevention and Director of the Pharmaceutical and Device Department of the Beijing Municipal Health Commission, Ma Limei, Deputy Director of the Beijing Medical and Health Technology Development Center, and Cheng Wanhui, Director of the Third Department of Industrial Promotion at the Zhongguancun Science City Management Committee, respectively gave reports introducing Beijing's biopharmaceutical industry and relevant policies from municipal commissions and offices.。On professional forums,FromMETiS TechBio's Co-founder and CEO, Cai-Da Lai, Delivered an Excellent Speech Titled "AI-Driven Drug Delivery and Drug Discovery"，Dr. Lai CaidaShowcased the innovative applications of AI technology in drug delivery and drug discovery, as well as its future prospects.# AI Technology: A Revolutionary Breakthrough in Drug DeliveryIn his speech, Dr. Lai Caida pointed out: "AI technology is rapidly transforming the landscape of the biopharmaceutical field, particularly in drug delivery and drug discovery."He mentioned that traditional drug delivery faces many challenges, includingHow to Precisely Deliver Drugs to the Disease Site, especially in organs other than the liver, such as the lungs, muscles, brain, and tumors.Dr. Lai explained: "We need a method that can parse vast amounts of interdisciplinary data to design highly efficient nanomaterials, significantly improving the precision and efficiency of drug delivery.”When introducing the innovative achievements and future vision of METiS TechBio, Dr. Lai Caida said: "METiS TechBio is committed to becoming the 'SpaceX' of the pharmaceutical industry by designing different 'nano-rockets' to unlock a trillion-dollar new market opportunity."He further elaborated on the 'three-step' strategy for drug development:"Decode, Design, and Deliver。By decoding the characteristics of different organ targets, targeted nanomaterials are designed to achieve efficient drug delivery., which will completely change the traditional model of drug delivery.Dr. Lai Caida also mentioned that the application of AI technology in drug delivery is not limited to theoretical research. He illustrated how METiS TechBio utilizes AI technology to optimize drug delivery materials and has achieved significant results in multiple experiments: "Our delivery materials in the gene therapy field have demonstrated expression levels 20 to 30 times higher than the industry-leading materials, marking a breakthrough that brings new hope to the entire biopharmaceutical industry.”# Innovation and Breakthrough: Leading Technology of METiS TechBioNext, Dr. Lai Caida further exploredMETiS TechBio's Leading Technology in Nanomaterial Simulation and High-Throughput Experimentation, the company has developed a drug delivery material library with millions of entries, and is using AI technology for rapid screening and optimization: "Through AI, we are able to identify the optimal delivery materials from vast amounts of data, significantly enhancing the efficiency of drug delivery and the performance of therapeutic effects.”Currently, METiS TechBio is inBuilding the world's first large-scale drug delivery model and its accompanying dry-wet experimental platformHave achieved certain success, he said, "Our dry and wet experimental platform combines high-throughput screening technology with precise nanomaterial design, enabling us to conduct a large number of experiments in a short time and obtain reliable data support." This innovative approach not only improves the efficiency of drug delivery but also significantly reduces R&D costs.Dr. Lai Caida shared METiS TechBio'sGene Therapy, Nucleic Acid DrugsApplication cases in fields such as...". He pointed out: "Through AI technology, we can precisely deliver gene sequences to target cells, reprogram diseased cells, and restore them to health. This process is not only highly precise but also significantly enhances treatment efficacy."These technologies have broad application prospects and will be able to treat more complex diseases in the future, such as metabolic diseases, cancer, and central nervous system disorders, among others."# About METiS TechBio: Leading the Future of BiopharmaceuticalsAt the end of the speech, Dr. Lai Cai-da introduced in detail the background and future vision of METiS TechBio. METiS TechBio is a globally leading biopharmaceutical enterprise,Focus on leveraging AI technology to drive innovation in drug delivery and drug discovery. Founded in 2020, the company has successfully raised over 300 million US dollars and establishedThe World's First Large-Scale Drug Delivery Model and Its Accompanying Dry-Wet Experimental Platform。He mentioned: "Our goal is to develop more precise and efficient treatment solutions through technological innovation, bringing blessings to patients worldwide."METiS TechBio not only focuses on technology research and development but also is committed to promoting the development of the entire industry:"We hope that through our efforts, we can push forward the third pharmaceutical revolution, completely transforming the methods of drug delivery and drug discovery, making more precise and efficient treatments possible.”METiS TechBio's breakthrough technology and innovative concepts garnered significant attention and positive feedback at the conference. Dr. Lai Caida's presentation not only showcased the immense potential of AI in the biopharmaceutical field but also charted a course for the industry’s future development. He concluded, “AI technology offers us an unprecedented opportunity to address challenges that were once insurmountable. We will continue to invest substantial resources to further expand and optimize our AI platform, develop more innovative drugs, and bring greater benefits to patients.”
Zhongguancun Lianxin Bio-Medical Industry Alliance (referred to as “ZLSHIA”)Registered with the Beijing Civil Affairs BureauNational Non-profit Corporate Legal Person, aiming to respond to China's major strategic planning for the biopharmaceuticals industry, build a platform for communication between the government and enterprises, voice the concerns of the biopharmaceuticals industry alliance, promote collaborative innovation in industry, academia, and research, and boost the development of the biopharmaceuticals industry.The predecessor of the alliance was the "Zhongguancun Biomedical Industry Alliance".，In 2015, the prefix was added as required by the Ministry of Civil Affairs.Registered as"Zhongguancun Lianxin Biomedical Industry Alliance"The meaning of "Lianxin" is "United Innovation."AllianceFacingRecruitment Across ChinaRecruitBiopharmaceutical enterprises and research institutionsMember.AllianceProvide various resource对接services for member units. AlreadyCumulatively participated in promoting 15 industrial policy innovations; presided over or led the formulation of over 20 biopharmaceutical industry policies or plans for governments at all levels in China; presided over or participated in over 30 planning and consulting projects for various biopharmaceutical industrial parks nationwide; led or recommended member units to participate in over 50 major scientific and technological or platform projects; organized or co-organized more than 500 exhibitions, forums, and salon events.
